The Walgreens governance failure is the largest and most recent example of what NAVETRA™ identifies as Organisational Alignment failure at the strategy-execution level: a board approved a major strategic pivot, an executive chairman designed it, and then appointed a CEO to execute a complex healthcare transformation who had no healthcare experience — while retaining the power to override that CEO's decisions throughout. The result was not a failure of the strategy or of the CEO. It was a structural failure of the governance architecture that was supposed to ensure the right person was executing the right strategy with the right oversight. By the time the board acknowledged the failure, $90 billion of shareholder value had been destroyed.
What Actually Happened
Walgreens Boots Alliance was created in 2014 when the US drugstore chain Walgreens merged with the European pharmacy giant Alliance Boots, the business built and led by Italian billionaire Stefano Pessina. Pessina, who had taken Alliance Boots private with KKR in 2007, became the largest shareholder of the combined entity — holding approximately 17% — and served as CEO from 2015 to 2021, then as executive chairman. At its peak in 2015, the combined company was worth approximately $100 billion and was a component of the Dow Jones Industrial Average.
The decade that followed was defined by a single strategic bet that was designed by Pessina, executed poorly, and overseen by a board that was too slow to challenge either the strategy or the execution. Pessina's vision — described as turning Walgreens stores into "neighbourhood health destinations" — was a genuine strategic response to a genuine threat: the erosion of the retail pharmacy model by PBM margin compression, e-commerce displacement, and the growing relevance of healthcare delivery as a value-added service. It was not a foolish strategy. CVS Health executed a version of the same pivot — with the Aetna acquisition — and produced a different outcome. The difference was governance execution, not strategic direction.
2015: Stefano Pessina becomes CEO of Walgreens Boots Alliance after the Alliance Boots merger. Market cap approximately $100 billion. He begins articulating the vision of Walgreens as a healthcare delivery company, not just a pharmacy retailer.
2020: Walgreens makes its first investment in VillageMD — a primary care provider that operates clinics inside Walgreens stores — committing $1 billion and taking a majority stake. The logic: Walgreens locations can become destinations for primary care, differentiating the company from pure pharmacy competitors and Amazon. The board approves. No vertical integration infrastructure — no insurer partnership, no payor relationship — is in place to make the model profitable.
2021: Pessina steps down as CEO and becomes executive chairman — retaining the largest single shareholder position at 17% and retaining what analysts describe as "outsize power over the organisation." The board appoints Rosalind Brewer as CEO. Brewer is an accomplished retail and consumer executive — former COO of Starbucks, former president of Sam's Club. She has no healthcare or pharmacy experience. The board simultaneously approves an additional $5 billion investment in VillageMD and the acquisition of CareCentrix (home care), each approved while Brewer is being asked to execute a healthcare transformation that is outside her domain expertise.
2021–2023: VillageMD acquires Summit Health-CityMD in a $9 billion transaction. Walgreens' total exposure to VillageMD and healthcare assets reaches approximately $6.2 billion. The healthcare segment consistently underperforms against its timeline to profitability. Brewer describes each quarter as progress toward a goal that never arrives. Unlike CVS, which secured full vertical integration through the Aetna acquisition, Walgreens attempts to be an "independent partner" to every payor — and ends up with, in one analyst's description, "a Frankenstein-esque assemblage of assets."
September 2023: Rosalind Brewer resigns as CEO after 30 months. Analysts note that her departure is unsurprising — the strategy she was appointed to execute required healthcare expertise she did not have — but that the timing is abrupt. Pessina acknowledges the company will now search for a CEO with "deep healthcare experience." Ginger Graham serves as interim CEO. Tim Wentworth is appointed as permanent CEO in October 2023 — his first act is to acknowledge the scale of the problem.
2024 — February: Walgreens is removed from the Dow Jones Industrial Average, replaced by Amazon. The symbolic significance is considerable: the company that once defined American retail pharmacy is being replaced by the company most responsible for its structural decline.
2024 — October: Walgreens announces plans to close approximately 1,200 stores over three years — approximately 14% of its US locations. CEO Wentworth publicly acknowledges the company's business model is "non-sustainable" in its current form. The company takes a $6 billion impairment charge on VillageMD, effectively writing down the majority of its investment. Total losses for fiscal year 2024 reach $8.6 billion — an increase of 180% from 2023.
Early 2025: Walgreens suspends its dividend for the first time in over 90 years. The company begins exploring a full sale.
August 2025: Sycamore Partners completes the acquisition of Walgreens Boots Alliance at a total enterprise value of approximately $23.7 billion — an equity value of approximately $10 billion, a fraction of the company's $100 billion peak. Pessina reinvests his entire proceeds ($1.745 billion) into the private entity, retaining his stake. The company is immediately split into five standalone businesses.
The most precisely articulated diagnosis of the Walgreens failure came from a University of Chicago Booth School of Business professor commenting on the VillageMD strategy: "That was a very foolish area to go into from the jump. Walmart has done the same thing with much more money and a much bigger balance sheet, and they failed as well." And from a Raymond James analyst: "It's just kind of a war of attrition now." Neither comment is a governance observation. But both are the outputs of a governance architecture that failed to ask the right question at the right moment — which is: does the person we are asking to execute this strategy have the expertise to tell us when it isn't working?
"Rather than entrust the execution of his unprecedented strategy to a seasoned healthcare executive, he handed the reins to Brewer, a former retail executive at Starbucks and Sam's Club. She struggled to implement Pessina's vision. The CEO is going to have a shorter leash, not a longer leash — it might be a tough search to fill."
The Five NAVETRA™ Domains That Were Failing
NAVETRA™ measures the ten organisational and human domains that determine whether governance functions in practice. Walgreens' failure maps across five domains — not as a result of a single bad decision but as the compounding output of a governance architecture that misaligned strategy, leadership, capability, and oversight for a decade.
Is the board, the executive chairman, and the CEO working from the same shared picture of whether the healthcare strategy is working — or is the board receiving progress narratives from a CEO who was never positioned to challenge the strategy she was hired to execute?
At Walgreens: the Brewer appointment is the Leadership Alignment failure made visible. Pessina designed the strategy. Pessina retained executive chairman authority and 17% shareholder influence over subsequent decisions. The board then appointed a CEO with no healthcare experience to execute a healthcare transformation — creating a structural situation in which the CEO had no independent basis to challenge the strategy, the executive chairman had every incentive to defend it, and the board received progress updates that consistently described the transformation as on track, until the impairment charge made the reality impossible to maintain. Leadership Alignment at Walgreens failed because the board created a three-party governance structure — executive chairman, CEO, board — in which neither the CEO nor the board had the independent capability to assess whether the core strategy was viable.
Is the organisation structurally aligned to execute a healthcare transformation — with the internal capabilities, payor relationships, clinical expertise, and integration infrastructure required to make primary care delivery profitable at scale — or is it aligned to retail pharmacy operations attempting to become a healthcare company?
At Walgreens: the fundamental Organisational Alignment failure was the absence of the vertical integration that CVS secured through Aetna. CVS bought an insurer, giving it control of the payor relationship that determines whether primary care is profitable. Walgreens attempted to be an independent partner to every payor — which meant it controlled none of the incentive structures that make healthcare delivery economics work. The organisation was aligned to retail pharmacy operations, and the VillageMD clinics operated as a separate entity within a retail structure that could not convert patient visits into the value-based outcomes that would have made the model financially sustainable. Organisational Alignment failure at Walgreens was not about execution — it was about the absence of the structural conditions that would have made execution possible at all.
Did the board's CEO appointment process produce a leader with the specific expertise required to execute, evaluate, and if necessary challenge a complex healthcare transformation strategy — or did governance factors, including the executive chairman's influence and the board's existing relationships, produce a mismatched appointment?
At Walgreens: the Brewer appointment is the most consequential CEO hiring decision in the company's recent history, and the Hiring Friction failure it represents is structural rather than individual. Brewer was accomplished in retail and consumer — two domains entirely distinct from the capability requirements of a healthcare transformation. Analysts at the time of her departure explicitly noted that the company needed a CEO with "more extensive backgrounds in healthcare services" — an acknowledgement that the appointment had been mismatched from the outset. One professor described it as "a little unusual" that Pessina functioned "more like the boss than in a typical setup" during the search — which is the governance observation that explains the mismatch: the board's CEO appointment process operated in the shadow of an executive chairman who had designed the strategy and whose preferred approach influenced who was chosen to execute it.
Did the board have the structural capacity to independently assess the external risk environment — PBM margin compression, Amazon pharmacy disruption, the profitability trajectory of value-based care — and translate those signals into a governance challenge of the VillageMD strategy before $6.2 billion had been committed?
At Walgreens: the pharmacy benefit manager margin compression that eventually made large portions of Walgreens' core business unprofitable was visible to industry analysts throughout the period in which VillageMD was being built. Amazon Pharmacy's trajectory was visible. CVS's vertical integration strategy — and its structural advantages over Walgreens' independent partner approach — was visible. Walmart's simultaneous failure to execute a comparable healthcare pivot was visible before Walgreens had fully committed its capital. External Risk Readiness failure at Walgreens was the board's inability to independently stress-test the VillageMD strategy against the external environment — because the board lacked the healthcare domain expertise to challenge the executive chairman who had designed it, and the CEO who was executing it lacked the healthcare expertise to provide an independent assessment from the inside.
Were the retail pharmacy function, the healthcare delivery function, the financial function, and the board working from a shared, integrated picture of whether the healthcare assets were progressing toward profitability — or was each function reporting within its own framework, with no integrated governance view of the consolidated position?
At Walgreens: the VillageMD strategy failed in part because it was never fully integrated with Walgreens' core operations. The clinics operated inside Walgreens stores but not as part of an integrated financial or clinical model — there was no payor relationship that created shared incentives between Walgreens the pharmacy and VillageMD the primary care provider. The board received separate performance narratives for the retail pharmacy segment and the healthcare segment, without an integrated governance picture of whether the combined model was moving toward the structural profitability that justified the capital commitment. Cross-Functional Alignment failure at Walgreens is the board-level manifestation of the same strategic gap: the retail business and the healthcare business were treated as parallel narratives rather than as a single integrated governance risk that required a consolidated assessment.
The CVS Comparison — Same Problem, Different Governance
The most instructive external benchmark for the Walgreens governance failure is CVS Health. CVS faced the same structural challenge — pharmacy margin compression, Amazon disruption, the opportunity in healthcare delivery — at roughly the same time. CVS's response was the $69 billion acquisition of Aetna in 2018, which gave it the insurer relationship required to make value-based care financially viable. CVS controls the payor. Walgreens tried to be the partner of every payor. The strategic difference produced the financial difference.
The governance lesson from the CVS comparison is not that Walgreens should have bought an insurer. It is that a board governing a healthcare transformation strategy should have had the independent capability — either through board composition, external advisory, or CEO domain expertise — to ask the strategic question that the CVS/Aetna outcome makes visible: without a payor relationship, how does this model reach profitability? The Walgreens board either never asked that question, or asked it too late to change the outcome.
$100 billion to $10 billion. Removed from the Dow Jones. $6.2 billion in VillageMD investment followed by a $6 billion impairment. First dividend suspension in 90+ years. Five CEOs in ten years. A healthcare transformation strategy designed by the executive chairman and handed to a CEO with no healthcare experience to execute. An admission in October 2024 that the business model was "non-sustainable." A $23.7 billion forced sale to private equity. Walgreens is the largest and most current available case study in Leadership Alignment failure at the strategy-execution level: a board that approved a major strategic pivot, an executive chairman who designed it, a CEO appointment that mismatched the execution requirement, and no independent governance mechanism capable of assessing whether the strategy's missing structural component — vertical integration — made the entire investment unviable. By the time the board acknowledged the problem, 93% of shareholder value had been destroyed.
The Question for Every Board Governing a Major Strategic Pivot
The Walgreens governance failure poses a specific question for every board that is governing a company through a major strategic transformation into an adjacent sector: does the board have — independent of the CEO and the executive chairman — the domain expertise to assess whether the strategy's structural preconditions for success are in place?
At Walgreens, those preconditions included a payor relationship. They were never in place. A board with independent healthcare expertise would have been positioned to identify this gap — not from the CEO's progress updates, not from the executive chairman's strategic vision, but from an independent assessment of what the CVS model demonstrated about the structural requirements for making healthcare delivery profitable from a pharmacy platform.
NAVETRA™ measures whether the five domains that determine board independence and strategic alignment are functioning. At Walgreens, Leadership Alignment, Organisational Alignment, Hiring Friction, External Risk Readiness, and Cross-Functional Alignment were all failing simultaneously — not from negligence, but from a governance architecture that concentrated strategic authority in an executive chairman, delegated execution to a mismatched CEO, and left the board without the independent capability to challenge either. The result was a decade of destruction in plain sight.
The most expensive governance failure is not the strategy that didn't work. It is the governance architecture that was incapable of identifying that the strategy was missing its most critical structural component — before $6.2 billion had been invested in proving it.